



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Bravecto 500 mg spot-on solution for medium-sized dogs (>10 - 20 kg) Vm 01708/5026

10 December 2024	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible.
24 January 2024	Alignment of product information with the national SPC/QRD template.
12 June 2023	Unlimited renewal.
22 June 2022	Change in name of manufacturer of the active substance.
08 April 2022	Changes to the labelling and/or package leaflet.
30 July 2021	Addition of a pair of gloves per pipette in the carton box.
06 May 2021	Addition of a primary packaging site. Addition of a secondary packaging site. Change in the manufacturing process of the finished product. Change in the manufacturing process of the finished product. Addition of a bulk manufacturing site.
04 March 2021	Deletion of site where batch control takes place